For example, the pivotal FIGHT-202 trial (NCT02924376) reported partial responses in a small subset of cholangiocarcinoma patients harboring non-FGFR2 alterations (e.g., other FGF/FGFR pathway abnormalities) or even no detectable FGF/FGFR alterations. Here, FGFR2 is linked to cholangiocarcinoma.